$21.42
0.331.56%
Ult. Agg.: Oct 20, 4:00 PM
Anika Therapeutics (ANIK) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
Anika Therapeutics (ANIK) ha pubblicato l'ultima guidance il luglio 29, 2026 per fiscal year 2026. La società ha previsto un fatturato pari a $118.46M - $124.1M per il periodo.
Rispetto alle previsioni precedenti, Anika Therapeutics ha modificato le sue previsioni di fatturato da un intervallo precedente di .
Anika Therapeutics ha pubblicato {{revenueDirection}} aggiornamenti delle previsioni tra il {{revenuePriorRange}} e il Anika Therapeutics. 10
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $-0.01 | $-0.04 | $-0.06 | $-0.06 |
| Actual | $0.42 | $0.27 | $0.31 | $0.04 |
| Surprise | +4300.0% | +775.0% | +616.7% | +166.7% |
| Revenue | ||||
| Estimate | $29.2M | $28.1M | $28.9M | $27.8M |
| Actual | $32.6M | $29.6M | $30.6M | $27.8M |
| Surprise | +11.6% | +5.23% | +6.02% | 0.00% |
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $0.39 | $0.16 | $0.04 | $0.17 |
| Revenue | ||||
| Consensus | $29.4M | $30.0M | — | — |
| Trimestre fiscale | Data segnalata | EPS effettivo | EPS stimato | Sorpresa% |
|---|---|---|---|---|
| Q2 | Jul 29, 2026 | $0.42 | $-0.01 | 4300.0 % |
| Q1 | Apr 29, 2026 | $0.27 | $-0.04 | 775.0 % |
| Q4 | Feb 26, 2026 | $0.31 | $-0.06 | 616.7 % |
| Q3 | Nov 5, 2025 | $0.04 | $-0.06 | 166.7 % |
| Trimestre fiscale | Data segnalata | Entrate effettive | Entrate stimate | Sorpresa% |
|---|---|---|---|---|
| Q2 | Jul 29, 2026 | $32.61M | $29.22M | 11.6 % |
| Q1 | Apr 29, 2026 | $29.61M | $28.14M | 5.23 % |
| Q4 | Feb 26, 2026 | $30.62M | $28.88M | 6.02 % |
| Q3 | Nov 5, 2025 | $27.80M | $27.80M | 0.00 % |